TATLI, A. M. Et Al. 2021. Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study. Journal of B.U.ON. , vol.26, no.6 , 2457-2464.

TATLI, A. M., Yumuk, P. F., Oz, B., Bilici, A., Gursoy, P., Goker, E., ... Sezer, A.(2021). Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study. Journal of B.U.ON. , vol.26, no.6, 2457-2464.

TATLI, ALİ Et Al. "Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study," Journal of B.U.ON. , vol.26, no.6, 2457-2464, 2021

TATLI, ALİ M. Et Al. "Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study." Journal of B.U.ON. , vol.26, no.6, pp.2457-2464, 2021

TATLI, A. M. Et Al. (2021) . "Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study." Journal of B.U.ON. , vol.26, no.6, pp.2457-2464.

@article{article, author={ALİ MURAT TATLI Et Al. }, title={Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study}, journal={Journal of B.U.ON.}, year=2021, pages={2457-2464} }